Both are cases of great products and questionable business acumen (to be charitable). To be fair, Rock Mackie was keenly aware of the disconnect between creating a good technology and satisfying shareholders who wouldn't know a transformative cancer treatment from a hole in the ground. That's why he resisted overtures to take Tomo public sooner.
I hope the acquisition works out for both sides. I also hope (but am not optimistic) that the business leadership takes a turn for the better. If Euan Thompson maintains his CEO position, he needs to do better than he has.
On a side note, re: the "premium" share price paid out to Tomo stockholders. I know a few people in Madison that are probably still holding their IPO offering at about $13/share that are saying words unsuitable for this forum right about now. Quelle dommage.